Phase 1/1b Study of Rilotumumab in Japanese Subjects With Advanced Solid Tumors or Advanced or Metastatic Gastric or GEJ
Conditions
- Part 1- Advanced Solid Tumors
- Part 2- Advanced or Metastatic Gastric Cancer
- Part 2- Advanced or Metastatic GEJ
Interventions
- DRUG: Rilotumumab
- DRUG: Rilotumumab
Sponsor
Amgen